Recent advances in the headache-cerebrovascular disease relationship

Objective

This virtual issue highlights recent reviews and original research published in Headache on the topic of CV disease and headache. With the exception of a 2020 narrative review of the relationship of migraine and ischemic stroke, the papers were published in 2021, 2022, and early 2023. The first section focuses on populations of individuals with migraine (stratified by headache frequency) and with aura or aura-like events, detailing investigations of clinical characteristics and etiologies that may predispose to stroke. The second section includes papers examining the relationship of headache and CV events, including migraine as an ischemic stroke risk factor and headache following aneurysmal subarachnoid hemorrhage or cervicocerebral dissection. Papers in the third section focus on cardiovascular risk in persons on migraine therapeutics, specifically triptans for acute treatment and erenumab, a fully human monoclonal antibody to the calcitonin gene–related peptide receptor, for migraine prevention.

Activity Disclosures 

No commercial support has been accepted related to the development or publication of this activity.

Rashmi B. Halker Singh, MD, FAHS, FAAN – Dr. Halker Singh has served on Advisory Boards for Impel and Teva.

Larry Charleston IV, M.D., M.Sc., FAHS – Dr. Charleston has received personal compensation for serving as a consultant for Allergan/AbbVie, Amneal, Biohaven, Haleon, LinPharma, Satsuma, and Teva; was on the advisory panel for Ctrl M Health (stock); received grant/research support from the Disparities in Headache Advisory Council and Amgen.

Anders Hougaard, MD – Dr. Hougaard has received honoraria for lecturing and/or writing from Abbvie, Novartis, Lundbeck, and Eli Lilly.

All other faculty report no relevant financial relationships. This activity underwent peer review in line with standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Accreditation
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 4.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

The American Board of Psychiatry and Neurology has reviewed Recent advances in the headache-cerebrovascular disease relationship and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

This activity is designed to be completed within 4.0 hours. To successfully earn credit, participants must access and complete the activity during the valid credit period, which is up to two years from initial publication.